Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD

Nutt, John G.; Burchiel, Kim J.; Comella, Cynthia; Jankovic, Joseph; Lang, Anthony E.; Laws, Edward R.; Lozano, Andrés M.; Penn, R. D.; Simpson, Richard K.; Stacy, Mark; Wooten, G. F.; Group*, the ICV GDNF Study

doi:10.1212/wnl.60.1.69

articleNeurologyJan 14, 2003Closed access

Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD

JGJohn G. Nutt KJKim J. Burchiel CCCynthia Comella JJJoseph Jankovic AEAnthony E. Lang

Rush University Medical Center

PubMed

Indexed incrossrefpubmed

Abstract

Objective

To assess the safety, tolerability, and biological activity of glial cell line-derived neurotrophic factor (GDNF) administered by an implanted intracerebroventricular (ICV) catheter and access port in advanced PD.

Background

GDNF is a peptide that promotes survival of dopamine neurons. It improved 6-OHDA- or MPTP-induced behavioral deficits in rodents and monkeys.

Citation impact

820

total citations

FWCI: 17.19
Percentile: 100%
References: 15

Citations per year

Authors

12

Topics & keywords

Topics

Keywords

Glial cell line-derived neurotrophic factor
GDNF family of ligands
Neurotrophic factors
Randomized controlled trial
Medicine
Neuroscience
Ciliary neurotrophic factor
Double blind

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.